RT Journal Article
SR Electronic
T1 Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260744
DO 10.1101/2021.07.19.21260744
A1 Yamamoto, Shohei
A1 Fukunaga, Ami
A1 Tanaka, Akihito
A1 Takeuchi, Junko S.
A1 Inoue, Yosuke
A1 Kimura, Moto
A1 Maeda, Kenji
A1 Ueda, Gohzoh
A1 Mizoue, Tetsuya
A1 Ujiie, Mugen
A1 Sugiura, Wataru
A1 Ohmagari, Norio
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260744.abstract
AB High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38□ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.Competing Interest StatementAntibody test reagents were provided by Abbott Japan. Gohzoh Ueda is an employee of Abbott Japan.Funding StatementThis work was funded by Abbott Japan (grant number 20C050), the NCGM COVID-19 Gift Fund (grant number 19K059), the Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09), and a grant from the National Center for Global Health (grant number 21A006).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of National Center for the Global Health and Medicine, Japan (the approved number: NCGM-A-004175)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to ethical restrictions and participant confidentiality concerns.